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Rezumat
Determinarea calitativă a furosemidului în urina sporti-
vilor prin metoda HPLC-SM/SM
A fost elaborată o metodă sensibilă şi simplă de determinare 
a furosemidului în urina sportivilor prin metoda HPLC 
– spectrometria de masă. Au fost optimizate condiţiile 
acestei metode. Metoda elaborată este utilizată cu succes 
pentru determinarea furosemidului în urina sportivilor ca 
un compus doping.
Cuvinte-cheie: HPLC, spectrometru de masă, furosemid, 
testare doping
Резюме
Kачественное определение фуросемида в моче 
спортсменов методом УВЭЖХ-MС/MС
Разработан чувствительный, селективный и простой 
метод определения фуросемида в моче спортсменов 
методом Ультра высокоэффективной жидкостной 
хроматографии масс-спектрометрии (УВЭЖХ-MС/
MС). Были оптимизированы условия как жидкостной 
хроматографии ,  так  и  масс-спектрометрии . 
Разработанный метод был успешно использован для 
определения фуросемида в моче спортсменов как 
допинговое соединение.
Ключевые слова: УВЭЖХ, масс-спектрометр, 
фуросемид, допинг-тест
Introduction
It is well known that furosemide is used as a di-
uretic in medicine. Due to this property, the athletes 
who compete in weight class sports such as boxing, 
wrestling and weightlifting, effectively use it to re-
duce the body weight, and also as a masking agent 
to conceal the other prohibited compounds in the 
body fluids by ample urination [1, 2]. That is why fu-
rosemide and its derivatives are considered as doping 
compounds and included to the WADA’s prohibited 
list of chemical substances [3]. Diuretics are ranked 
third (14% positive doping tests) after anabolic stero-
ids (54%) and stimulants (29%) among the prohibited 
compounds abused by the athletes [1].
Materials and methods
Instrumentation and Chemicals
Ultimate 3000 Quaternary Standard ultra-high 
performance liquid chromatography tandem TSQ 
Quantum Access Max triple quadrupole mass-
spectrometer (UHPLC-МS/МS) from Thermo Fisher 
Scientific was used throughout the study. The UHPLC 
column used was a HyperSil Super Gold C18 (100 
mm×2.1 mm, 1.9 μm) (Thermo Fisher Scientific, USA). 
Furosemide 1% 2 ml (10 μg/μL) aqueous solution 
and tablets containing 40 mg of active compound 
produced by the local pharmaceutical company was 
purchased from the local drug store. HPLC grade 
acetonitrile was purchased from Sigma-Aldrich Tra-
ding Co (Schnelldorf, Germany). Orthophosphoric 
acid and sodium hydroxide (purity >98.0%) was 
purchased from the local chemical company that 
specializes on the trade of chemical reagents and 
equipment. HyperSep Retain PEP SPE cartridges 
were obtained from Thermo Fisher Scientific (CA, 
USA). Ultrapure water was prepared by a water 
purification system from Sartorius Lab Instruments 
GmbH Et Co. KG (Goettingen, Germany). All other 
chemicals were analytical grade and used without 
further purification.
Sample Preparation
Standard furosemide containing urine sample 
was prepared by adding 2 ml 1% intramuscular 
solution (10 μg/μL) of furosemide to 98 ml of urine 
to make a total of 100 ml. From this 0.75 ml aliquots 
have been taken into 3 eppendorf tubes to add 
the equivalent amounts of water, 3% solution of 
orthophosphoric acid and 3% solution of sodium 
hydroxide solution, respectively. The samples were 
applied into HyperSep Retain PEP SPE cartridges ac-
tivated with 1 ml of methanol and equilibrated with 
methanol – water (containing 1% H3PO4 solution) – 
5-95 v/v. The analytes were eluted out with 0.75 ml 
of pure methanol. The obtained samples were then 
dried by a vacuum concentrator and reconstituted 
in 1 ml of mobile phase containing acetonitrile – 
water in a volume ratio of 35:65 (v/v) and passed 
through 0.2 μm Millipore filter. 1 μL of the samples 
were injected into UHPLC-MS/MS equilibrated in 
the above mentioned mobile phase in an isocratic 
elution mode.
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The UHPLC-MS/MS analysis of urine sample. (A) liquid 
chromatography profile of furosemide containing 
standard urine sample; (B) liquid chromatography pro-
file of urine sample collected after taking furosemide 
tablet; (C) mass-spectrometry profile of urine samples 
containing furosemide. The presence of furosemide was 
confirmed with its characteristic negative ion m/z 329 
shown in negative SIM mode.
Results and discussions
Many existing procedures for the determination 
of diuretics in literature outline quite complex and 
expensive methods. In doping control, diuretics 
extraction from urine includes multistep treatment 
with rare chemicals, following by chromatographic 
separation and data interpretation of the obtained 
spectral results. The lack of expensive rare chemical 
reagents and equipments as well as time-consuming 
tedious methods led us to modify more reliable and 
cheaper ways of analysis of drugs that is abused by 
the athletes. Therefore, the main goal of this research 
was to simplify the analysis of furosemide in urine.
Initially, for the method development, 100 ml of 
standard urine samples both containing furosemide 
and without furosemide were prepared in vitro (the 
ultimate concentration of furosemide in furosemide 
containing sample was 200 ng/μl). The in vivo urine 
samples were collected before and after taking 1 
tablet of furosemide that contain 40 mg of active 
compound.
The MS was operated in negative HESI-II mode, 
with data collected from 1-10 min. Initially, full scan 
Q1 mass spectra was acquired over the range of m/z 
50-1500 then SIM mode was applied for qualitative 
analyses of furosemide in urine. The SIM mode was 
more sensitive in comparison with full scan mode in 
selection of ions. It is because in the last one, typical-
ly, two transitions precursor-products are only moni-
tored that can mostly give sufficient information to 
define the necessary compound. In our research, the 
SIM mode was also successfully applied in defining 
furosemide parent ion from other concomitant ions 
having the same m/z present in urine.
Conclusion
The developed method proved the suitability of 
liquid chromatography-tandem mass spectrometry 
for the confirmation of the presence of furosemide 
in urine. The method was found to be selective and 
reliable towards furosemide, since the other compo-
nents of urine do not interfere with its detection.
Sample preparation and the analysis times 
have been reduced and simplified. The reduction 
of time and optimization of the developed method 
allowed achieving chromatographic separation of fu-
rosemide in short time (within 2 minutes). Selection 
of diagnostic fragmentation reactions and optimal 
collision energies allowed to achieve high selectivity 
in searching the necessary ion fragments.
The developed method was qualitatively vali-
dated to be used in anti-doping tests.
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